Sentinel lymph node biopsy in head and neck rhabdomyosarcoma.
Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R.
Pediatric Blood and Cancer.
2019;
66.
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois, SG; Mosse, YP; Fox, E; Kudgus, RA; Reid, JM; McGovern, R; Groshen, S; Bagatell, R; Maris, JM; Twist, CJ; et al.
Clinical Cancer Research.
2018;
24:6142-6149.
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher, MJ; Belzberg, AJ; de Blank, P; De Raedt, T; Elefteriou, F; Ferner, RE; Giovannini, M; Harris, GJ; Kalamarides, M; Karajannis, MA; et al.
American Journal of Medical Genetics, Part A.
2018;
176:1258-1269.
Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors.
Sirignano, M; Dillman, JR; Weiss, BD; Quinn, CT; Zhang, B; Su, W; Trout, AT.
Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI.
2018;
48:325-332.
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
Marachelian, A; Villablanca, JG; Liu, CW; Liu, B; Goodarzian, F; Lai, HA; Shimada, H; Tran, HC; Parra, JA; Gallego, R; et al.
Clinical Cancer Research.
2017;
23:5374-5383.
Congenital Sucrase-isomaltase Deficiency: A Novel Compound Heterozygous Mutation Causing Aberrant Protein Localization.
Haberman, Y; Di Segni, A; Loberman-Nachum, N; Barel, O; Kunik, V; Eyal, E; Kol, N; Hout-Siloni, G; Kochavi, B; Avivi, C; et al.
Journal of Pediatric Gastroenterology and Nutrition.
2017;
64:770-776.
Significant and Sustained Reduction in Chemotherapy Errors Through Improvement Science.
Weiss, BD; Scott, M; Demmel, K; Kotagal, UR; Perentesis, JP; Walsh, KE.
(2017)
AMER SOC CLINICAL ONCOLOGY.
13:e329-e336.
Single and multidimensional measurements underestimate neuroblastoma response to therapy.
Trout, AT; Towbin, AJ; Klingbeil, L; Weiss, BD; von Allmen, D.
Pediatric Blood and Cancer.
2017;
64:18-24.
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi, E; Baldwin, A; Marcus, LJ; Fisher, MJ; Weiss, B; Kim, A; Whitcomb, P; Martin, S; Aschbacher-Smith, LE; Rizvi, TA; et al.
The New England journal of medicine.
2016;
375:2550-2560.